TY - JOUR T1 - Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. AU - Bajema,Kristina L, AU - Dahl,Rebecca M, AU - Evener,Steve L, AU - Prill,Mila M, AU - Rodriguez-Barradas,Maria C, AU - Marconi,Vincent C, AU - Beenhouwer,David O, AU - Holodniy,Mark, AU - Lucero-Obusan,Cynthia, AU - Brown,Sheldon T, AU - Tremarelli,Maraia, AU - Epperson,Monica, AU - Mills,Lisa, AU - Park,So Hee, AU - Rivera-Dominguez,Gilberto, AU - Morones,Rosalba Gomez, AU - Ahmadi-Izadi,Ghazal, AU - Deovic,Rijalda, AU - Mendoza,Chad, AU - Jeong,Chan, AU - Schrag,Stephanie J, AU - Meites,Elissa, AU - Hall,Aron J, AU - Kobayashi,Miwako, AU - McMorrow,Meredith, AU - Verani,Jennifer R, AU - Thornburg,Natalie J, AU - Surie,Diya, AU - ,, AU - ,, AU - ,, Y1 - 2021/12/10/ PY - 2021/12/9/entrez PY - 2021/12/10/pubmed PY - 2021/12/15/medline SP - 1700 EP - 1705 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 70 IS - 49 N2 - The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.†. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/34882654/Comparative_Effectiveness_and_Antibody_Responses_to_Moderna_and_Pfizer_BioNTech_COVID_19_Vaccines_among_Hospitalized_Veterans___Five_Veterans_Affairs_Medical_Centers_United_States_February_1_September_30_2021_ DB - PRIME DP - Unbound Medicine ER -